Siolta Therapeutics

11/19/2025

Great to see federal leadership— , , , , —aligned on the need to prevent & treat allergic diseases. Even better to hear consensus that microbiome science may be key to new solutions.

At , allergic disease prevention has been our focus from day one. It affects 1 in 4 kids (and 1 in 2 in at-risk families). We need to stop these diseases before they start.

Thanks to & Ilana Golant for the spotlighting both the challenge and emerging solutions, including our trial.

Full coverage ⤵️

With over 32 million Americans facing food allergies, HHS Secretary RFK Jr. and FDA Chief Makary explore microbiome solutions. New gut health research may hold the key.

08/02/2023

We are excited to share an article from Ron Leuty talking about Siolta Therapeutics and our mission to stop allergic diseases before they start. To learn more, please visit the adoredstudy.com website for more information.

https://rb.gy/47hvh

07/26/2023

We are excited to share a blog published by Classified Mom. We are happy to see so many moms interested in spreading the word about our Adored Study (adoredstudy.com) for the potential prevention of allergic diseases in newborns.

https://www.classifiedmom.com/could-research-into-babies-microbiome-prevent-lifelong-allergies-later-in-life/

Certain babies are at a higher risk of developing allergic diseases like atopic dermatitis (allergic eczema), food allergy, asthma, and allergic rhinitis (hay

07/13/2023

We are excited to be featured by Motherhood Moment, where a mom blogger interviewed us about the Adored Study for the prevention of allergic diseases. Enjoy the reading!

Poopy babies are needed to help other babies affected by allergic diseases like atopic dermatitis (allergic eczema), food allergy, asthma,...

06/13/2023

We are excited to share some recent highlights from Genetic Engineering & Biotechnology News (GEN) about our work at Siolta Therapeutics. We're pioneering the development of live bacterial products (LBPs) aimed at restoring health by rebalancing the microbiome.

At Siolta, we believe understanding and leveraging the microbiome's systemic impact can revolutionize how we approach a wide range of diseases. We're not just treating disease but preventing it - a true game changer in healthcare.

Our lead product, STMC-103H, is currently under a Phase II trial (the ADORED Study) for preventing atopic dermatitis in newborns. It aims to reprogram the microbiome of children who have a microbial signature linked to disease-driving metabolic and immunological functions. For more information, please visit www.adoredstudy.com.

We also have preclinical programs focused on recurrent bacterial vaginosis, a condition that affects women's ability to have healthy pregnancies, and necrotizing enterocolitis, a rare pediatric indication affecting preterm babies.

Read the full article here: https://lnkd.in/d9vEBK6k

Thank you for your support as we continue to push the boundaries of microbiome science!

Knowing the differences between peaceable and fractious microbiomes helps biotech companies create diagnostic tools and therapeutic interventions.

11/10/2022

Please join our CEO, Nikole Kimes, at the Microbiome Connect USA conference taking place in Boston next week for a Fireside Chat with Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA.

Our team will be there and look forward to reconnecting with existing and potential new partners. We hope to see you there.

The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic...

10/17/2022

We are excited to be part of WuXi AppTec's interview series on "Delivering on the Promise of New Modalities." What an incredible initiative from WuXi. Enjoy the reading!

View the full interview here:

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – […]

07/20/2022

I could not be more proud of the Siolta team as we announce the dosing of our first newborn in the Phase 2 portion of our adored study with STMC-103H, a novel LBP consortium. We have managed to navigate the difficult path of addressing chronic disease from a transformative new approach that aims to stop disease before it ever starts! This safety, tolerability, and efficacy study to prevent the onset of atopic diseases in newborns will allow provide crucial information to better understand the role that the microbiome plays in not only disease, but also in maintaining human health. I am grateful to the entire Siolta team, our investigators, and most importantly to the families participating in this prevention study as we work together to find novel approaches to address the growing burden of atopic diseases.

Siolta doses first newborn in phase 2 study for the prevention of atopic diseases.

02/09/2022

Excited to announce support from NIAID through an Advanced Technology Small Business Innovation Research Grant. Thanks to the Siolta team for all of their hard work and innovative approaches!

Siolta Therapeutics awarded NIH grant to further optimize its proprietary anaerobic biotherapeutics manufacturing and analytical processes.

01/19/2022

Interested in making a difference in healthcare through the human microbiome? Siolta is combining innovative approaches with the emerging microbiome therapeutics field to pursue transformative change in the way we approach chronic diseases. As a clinical stage biotech company, we are looking for microbiome scientists to help support both our preclinical and clinical translation programs.

05/14/2021

Food for thought regarding drug development, patent rights, and global distribution. Clifford Samuel and Claudio Liliendfeld provide some perspective in this Biocentury guest article:

The debate about whether to suspend patent rights for COVID vaccines doesn’t need to be an “us vs.